전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-1 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,016 programs
CGTLimited DatastaleAskBio IncPhase 1

d3990 (rAAV2.5-CMV-minidystrophin, rAAV2.5-CMV-minidystrophin (d3990))

Duchenne Muscular Dystrophy · Duchenne Muscular Dystrophy

#DuchenneMuscularDystrophy#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleEunice Kennedy Shriver National…Phase 1

recombinant adenovirus containing the ornithine transcarbamylase gene (recombinant adenovirus containing the ornithine transcarbamylase gene)

Ornithine Transcarbamylase Deficiency Disease · Ornithine Transcarbamylase Deficiency Di

#OrnithineTranscarbamylaseDeficie#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
AntibodyLimited DatastaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, relatlimab+nivolumab)

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#monoclonal-antibody#Bristol
Trials 1Status Active
AntibodyLimited DatastaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, relatlimab+nivolumab+rHuPH20)

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#monoclonal-antibody#Bristol
Trials 1Status Recruiting
AntibodyLimited DatastaleGenentech, Inc.Phase 3

ranibizumab (rhuFab V2, rhuFab V2 (ranibizumab))

Macular Degeneration · Macular Degeneration

#MacularDegeneration#Antibody#Phase3#monoclonal-antibody#Genentech
Trials 1Status Active
CGTLimited DatastaleUltragenyx Pharmaceutical IncPhase 2

scAAV8OTC (scAAV8OTC)

Ornithine Transcarbamylase (OTC) Deficiency · Ornithine Transcarbamylase (OTC) Deficie

#OrnithineTranscarbamylaseOTCDefi#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleAudentes TherapeuticsPhase 2

scAAV9.U7.ACCA (scAAV9.U7.ACCA)

Duchenne Muscular Dystrophy · Duchenne Muscular Dystrophy

#DuchenneMuscularDystrophy#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleThe First Affiliated Hospital o…Phase 2

ssCART-19 cells combined with CD19+ feeding T cells (FTCs, ssCART-19 cells combined with CD19+ feeding T cells, ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion)

Acute Lymphoblastic Leukemia, Adult B-Cell · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleEli LillyPhase 2

toripalimab + cetuximab + platinum (three cycles, three cycles (toripalimab + cetuximab + platinum))

Locally Advanced Hypopharyngeal Carcinoma · Locally Advanced Hypopharyngeal Carcinom

#LocallyAdvancedHypopharyngealCar#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Recruiting
AntibodyLimited DatastaleVanderbilt-Ingram Cancer CenterPreclinical

ticilimumab (ticilimumab)

Melanoma · Melanoma

#Melanoma#Antibody#Preclinical#monoclonal-antibody#Vanderbilt-Ingram
Trials 1Status Discontinued
AntibodyLimited DatastaleGlaxoSmithKlinePhase 2

tositumomab (tositumomab)

Lymphoma, B-Cell · Lymphoma

#Lymphoma#Antibody#Phase2#monoclonal-antibody#B-Cell+1
Trials 1Status Active
AntibodyLimited DatastaleAstraZenecaPhase 3

anti-CTLA4 (tremelimumab, tremelimumab (anti-CTLA4))

Non - Small Cell Lung Cancer NSCLC · Non - Small Cell Lung Cancer NSCLC

#Non-SmallCellLungCancerNSCLC#Antibody#Phase3#monoclonal-antibody#AstraZeneca
Trials 1Status Active
CGTLimited DatastaleInstitute of Hematology & Blood…Phase 1

uCD7 CART (uCD7 CART)

Acute Myeloid Leukemia (AML); T Lymphoblastic Leukemia/Lymphoma · Acute Myeloid Leukemia (AML)

#AcuteMyeloidLeukemiaAML#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleBeth ChristianPhase 2

veltuzumab and milatuzumab (veltuzumab and milatuzumab)

Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#monoclonal-antibody#Beth
Trials 1Status Active
AntibodyLimited DatastaleAIDS Malignancy ConsortiumPhase 2

yttrium Y 90 ibritumomab tiuxetan (yttrium Y 90 ibritumomab tiuxetan)

AIDS-related Lymphoma; Adult Non-Hodgkin's Lymphoma · AIDS-related Lymphoma

#AIDS-relatedLymphoma#Antibody#Phase2#monoclonal-antibody#AdultNon-HodgkinsLymphoma+1
Trials 1Status Discontinued
AntibodyLimited DatastalePartner Therapeutics, Inc.Phase 2

MCLA-128 (zenocutuzumab, zenocutuzumab (MCLA-128))

Solid Tumours Harboring NRG1 Fusion; NSCLC Harboring NRG1 Fusion · Solid Tumours Harboring NRG1 Fusion

#SolidTumoursHarboringNRG1Fusion#Antibody#Phase2#monoclonal-antibody#NSCLCHarboringNRG1Fusion+1
Trials 1Status Recruiting

51 / 51 pages

← PreviousNext →